Article Details
Retrieved on: 2022-10-27 14:55:19
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Given atai's robust pipeline of treatment candidates and expected milestones, ROTH considers the biopharma a Buy and assigns it a $32 per share ...
Article found on: www.streetwisereports.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here